TrialBritish journal of cancer2020

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.

Toshiki Masuishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.